Immunohistochemistry or IHC
Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status
Modern Pathology 2021 September 8 [Link] Julia R Naso, Basile Tessier-Cloutier, Janine Senz, David G Huntsman, Andrew Churg Abstract p53 immunohistochemistry has long been proposed for the separation of benign from malignant mesothelial proliferations, with the older literature suggesting that any degree of positivity supported a diagnosis of mesothelioma. However, using modern immunohistochemistry platforms in…
Read MoreEvidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology
Cancer Cytopathology 2021 September 3 [Link] Ilaria Girolami, Ersilia Lucenteforte, Albino Eccher, Stefano Marletta, Matteo Brunelli, Paolo Graziano, Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone, Aldo Scarpa, Tao Huang, Liron Pantanowitz Abstract Cytology effusions are often the only material available for diagnosing malignant pleural mesothelioma (MPM). However, the cytomorphological features alone are not always diagnostic, and…
Read MoreLoss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
American Journal of Clinical Pathology 2021 August 31 [Link] Simone Terra, Anja C Roden 1, Eunhee S Yi, Marie Christine Aubry, Jennifer M Boland Abstract Objectives: Differentiating malignant pleural mesothelioma from benign reactive mesothelial processes can be quite challenging. Ancillary tests such as BRCA1-associated protein 1 (BAP1) immunohistochemistry and p16 fluorescence in situ hybridization (FISH)…
Read MoreSOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia
The American Journal of Surgical Pathology 2021 August 19 [Link] David B Chapel, Michelle S Hirsch Abstract Primary peritoneal malignant mesothelioma (MM) can demonstrate morphologic overlap with low-grade and high-grade tubo-ovarian serous neoplasms; it is also biologically and prognostically distinct from benign mesothelial proliferations. Currently, there is no single biomarker that can definitively distinguish these…
Read MoreIdentification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities
Journal of Experimental & Clinical Cancer Research 2021 August 17 [Link] Barbara Nuvoli, Barbara Antoniani, Roberta Libener, Antonio Maconi, Andrea Sacconi, Mariantonia Carosi, Rossella Galati Abstract Background: Based on previous studies highlighting that the induction of cyclooxygenase-2 (COX-2) and high prostaglandin E2 (PGE2) levels contribute to the pathogenesis of malignant pleural mesothelioma (MPM), and that…
Read MoreMalignant pleural mesothelioma with heterologous elements
Journal of Clinical Pathology 2021 August 10 [Link] Toshiaki Kawai, Reishi Seki, Kuniharu Miyajima, Hiroshi Nakashima, Takayuki Takeda, Tomoyuki Murakami, Keisuke Aoe, Kazunori Okabe, Keiichi Homma, Yoshitane Tsukamoto, Koichi Sunada, Yasuhiro Terasaki, Maki Iida, Hideki Orikasa, Kenzo Hiroshima Abstract Aims: Malignant pleural mesothelioma with heterologous elements (such as osseous, cartilaginous or rhabdomyoblastic differentiation) is very…
Read MoreMalignant pleural mesothelioma showing rare morphology indistinguishable from myxofibrosarcoma concomitant with EGFR-mutated lung adenocarcinoma: A case report
International Journal of Surgical Case Reports 2021 August [Link] Hiroko Onagi, Takuo Hayashi, Tsuyoshi Saito, Satsuki Kishikawa, Kazuya Takamochi, Kenji Suzuki Abstract Introduction and importance: Primary tumors of the pleura are rare, with malignant mesothelioma being the most common of these neoplasms. Pathological diagnosis of sarcomatoid mesothelioma can be more challenging than that of epithelioid…
Read MoreDiagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study
Pathology Oncology Research 2021 April 9 [Link] Sarah Adel Hakim, Hoda Hassan Abou Gabal Abstract Background: Epithelioid mesothelioma (EM) is the commonest subtype of malignant pleural mesothelioma. Its histopathological discrimination from reactive mesothelial hyperplasia (RMH) could be challenging. Thus, an immunohistochemical panel is mandatory for better discrimination. BAP1 is a newly identified diagnostic marker whose…
Read MoreUpdate on Diagnosing and Reporting Malignant Pleural Mesothelioma
Acta Medica Academica 2021 April [Link] Ivana Savic, Jeffrey Myers Abstract In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign mesothelial proliferations and other malignant tumors. Current recommendations for reporting histological sub-type and tumor grade are also reviewed. Particular emphasis is placed on immunohistochemical and…
Read MoreDiagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…
Read More